Medicinal Chemistry in CRO drug discovery

Matthew (Matt) Campbell is a Research Leader in the Small Molecule Drug Discovery division at Charles River Laboratories, responsible for leading the delivery of milestones for client drug discovery projects through the support of integrated project teams. Matt joined Charles River in 2021 and has worked on several client projects across a range of different therapeutic areas and target classes that span the stages the drug discovery process, from Hit Identification to Drug Candidate.

Prior to joining Charles River, Matt established a career in drug discovery over a 21-year period at GlaxoSmithKline, during which time he has led projects developing therapies that ranged from small molecule to antibody. He contributed to the delivery of two drug candidates, multiple pre-candidates and a number of molecular probes for cardiovascular-, respiratory- and oncology- focused projects. Matt was awarded four GSK Senior Vice President Exceptional Science Awards for strong scientific leadership, decision making and innovative ways of working. He is named author on twelve GSK patents, and on twenty journal publications following in the main successful CASE collaborations with teams at Universities of St. Andrews, Strathclyde, Cardiff and ESPCI Paris.

Matt completed a DPhil in Pure and Applied Chemistry in 2016 in conjunction with the University of Strathclyde while working at GSK, and he obtained an MSci in Chemistry with Medicinal Chemistry in 2000 at Imperial College, London.